Medpace Holdings, Inc. (MEDP) is a leading global full-service clinical contract research organization (CRO), providing comprehensive development services for drug, biologic, and medical device companies. Founded in 1992, the company's headquarters are located in Cincinnati, Ohio. Medpace Holdings, Inc. is publicly traded on the NASDAQ Stock Market under the ticker symbol 'MEDP'.
The organization's main purpose is to accelerate the global development of safe and effective medical therapeutics. Medpace accomplishes this by leveraging its scientific expertise in various therapeutic areas, such as oncology, cardiovascular diseases, metabolic diseases, and many others. The company conducts clinical trials in all phases (I-IV), collaborates on regulatory strategies, and oversees trial data management and analysis.
In addition to clinical research services, Medpace provides centralized laboratory services, imaging services, and clinical pharmacology services. It works with a vast range of organizations, from ambitious start-ups to larger multinational enterprises. Medpace prides itself on its therapeutic and regulatory expertise, combining it with practical operational ability to manage studies in over 50 countries.
Medpace stands out for its unique physician-led, integrated approach to conducting clinical trials. This method helps to streamline the development process and provides higher-quality results, helping their clients to bring products to market faster and more efficiently. Medpace's team of medical doctors, Ph.D. level scientists and coordinators contribute to Medpace’s reputable client-focused service.
It is also noteworthy that Medpace is committed to maintaining the highest level of professional and ethical standards. The company follows the guidelines set forth by Good Clinical Practice (GCP), International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), and other regulatory authorities.
In recent years Medpace has expanded organically as well as through strategic acquisitions to further enhance their service offerings and global footprints. The company continues to thrive and evolve in the ever-changing landscape of clinical research.
Medpace's wide range of services, dedication to quality, and continuous growth mark them as a key player in the CRO industry. Their work helps facilitate the development and approval of new medicines and medical devices, playing a vital role in improving global healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Medpace Holdings, Inc. announced strong financial results for the third quarter and first nine months of 2026, with revenue increasing 8.5% year-over-year to $716.0 million and GAAP net income reaching $137.5 million. The company also reported a 16.0% rise in EBITDA to $172.1 million. Medpace has updated its full-year 2026 financial guidance, forecasting revenue between $2.835 billion and $2.855 billion and diluted earnings per share in the range of $17.97 to $18.32, and approved a new $1.0 billion stock repurchase authorization through December 31, 2028.
Medpace Holdings is rated HOLD due to improving bookings and operational trends, but its valuation remains high. While strong backlog and rising awards support the investment case, reported revenue is inflated by pass-through services. The article suggests a neutral portfolio weight until sustained improvements in own-service growth and cash conversion can justify a higher rating, noting that the current price already discounts substantial execution.
Medpace (MEDP) closed down 1.64% in its latest trading session, underperforming the broader S&P 500 and Dow. The company is set to release its earnings on October 21, 2026, with analysts anticipating a 15.28% rise in EPS and a 7.4% increase in revenue year-over-year. Despite recent gains and a "Hold" rating from Zacks, its Forward P/E and PEG ratios suggest it trades at a premium compared to its industry.
Medpace (MEDP) stock saw a decline of 2.84% in the latest trading session, underperforming the broader market which registered gains. Despite this, the company's shares have risen 4.94% over the past month, exceeding its sector and the S&P 500. Investors are anticipating Medpace's upcoming earnings report on October 21, 2026, with analysts forecasting a significant increase in EPS and revenue year-over-year.
Medpace Holdings (NASDAQ: MEDP) has significantly outperformed the market over the last decade, with an annualized return of 35.2%. An initial investment of $100 in MEDP stock 10 years ago would now be worth $2,000.96, highlighting the power of compounded returns. The company currently has a market capitalization of $17.32 billion.
Medpace Holdings President & CEO, August J Troendle, sold 48,667 shares of the company stock for a total of $30,320,929, according to an SEC filing on October 1. The company, a contract research organization, reported a 17.24% revenue growth rate as of June 30, 2026, and has a P/E ratio of 35.13. Medpace Holdings shares were up 0.58% at $599.51 as of Friday morning.